OXiGENE Schedules Quarter Four and Fiscal Year-End 2006 Conference Call

OXiGENE Schedules Quarter Four and Fiscal Year-End 2006 Conference Call

Live Internet Webcast to be Available at www.oxigene.com

    WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 20, 2007--Regulatory News:

    OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of
biopharmaceutical compounds to treat cancer and certain ophthalmologic
diseases, will announce its fourth quarter and Fiscal Year 2006
results on Tuesday, March 6, 2007 prior to the opening of the NASDAQ
Stock Market, followed by a conference call at 10:00 a.m. EST.

    OXiGENE's President and Chief Executive Officer, Dr. Richard Chin,
Chief Financial Officer, James Murphy, Chief Medical Officer, Dr.
Peter Harris and Chief Scientific Officer, Dr. David Chaplin, will
host the call.

    To listen to a live or an archived version of the audio webcast,
please log on to the Company's website, www.oxigene.com. Under the"Investor Center" tab, click on the link to "Presentations &
Conference Calls."

    OXiGENE's earnings conference call can also be heard live by
dialing (800) 819-9193 (U.S. and Canada) or (913) 981-4911
(international) five minutes prior to the call. A replay will be
available starting at 1:00 p.m. EST on March 6, 2007 and ending at
midnight EST on March 12, 2007. To access the replay, please dial
(888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international) and
refer to reservation number 4907164.

    About OXiGENE, Inc.

    OXiGENE is a biotechnology company developing novel small-molecule
therapeutics to treat cancer and eye diseases. The Company's major
focus is the clinical advancement of drug candidates that selectively
disrupt abnormal blood vessels associated with solid tumor progression
and visual impairment. OXiGENE is dedicated to leveraging its
intellectual property position and therapeutic development expertise
to bring life saving and enhancing medicines to patients.

                         Safe Harbor Statement

    Certain statements in this news release may be considered"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Any or all of the
forward-looking statements in this press release may turn out to be
wrong. They can be affected by inaccurate assumptions OXiGENE might
make or by known or unknown risks and uncertainties, including, but
not limited to: the early stage of product development; the ability to
secure necessary patents; uncertainties as to the future success of
ongoing and planned clinical trials; and the unproven safety and
efficacy of products under development. Consequently, no
forward-looking statement can be guaranteed, and actual results may
vary materially. Additional information concerning factors that could
cause actual results to materially differ from those in the
forward-looking statements is contained in OXiGENE's reports to the
Securities and Exchange Commission, including OXiGENE's Form 10-Q, 8-K
and 10-K reports. However, OXiGENE undertakes no obligation to
publicly update forward-looking statements, whether because of new
information, future events or otherwise.


CONTACT: OXiGENE, Inc.
Investor Relations, 781-547-5900